Europe Left Ventricular Assist Device Market Forecast to 2028 - Regional Analysis - by Type of Flow, Design, and Application

The Europe left ventricular assist device market is expected to grow from US$ 336.52 million in 2022 to US$ 445.05 million by 2028. It is estimated to grow at a CAGR of 4.8% from 2022 to 2028.

Increased Use of Artificial Intelligence and Machine Learning in LVAD Drive Europe Left Ventricular Assist Device Market

The increased incidence of complications and adverse events associated with LVAD encouraged manufacturers to develop innovative technologies and integrate new technologies into the devices. In several cases, patients with LVAD devices experience right ventricle failure leading to blood buildup in veins and swelling. To reduce the failure, manufacturers have integrated artificial intelligence (AI) to monitor the right ventricle with LVAD. Therefore, any change in the right ventricle activity and function will be reported to the healthcare professional, reducing the chances of right ventricle failure and complications.

Furthermore, the increased use of machine learning (ML) for developing risk scores for heart failure mortality provides an edge over conventional methods. Additionally, telemetry data analysis from wearable devices helps predict heart failure hospitalizations. Machine learning algorithms are used to access tricuspid annulus excursion on 2D and 3D echocardiography, which helps in the assessment of right ventricle function. Moreover, machine learning-based algorithms use 3D echocardiographic images to study the right ventricle volume and ejection fraction, providing exact data and efficient automated analysis of heart function.

Therefore, the use of artificial intelligence and machine learning algorithms helps develop a risk prediction model based on right ventricle functions in end-stage heart failure patients with LVAD. The risk stratification for right ventricle failure is one of the significant factors that help determine the patients’ survival. Therefore, the use of artificial intelligence and machine learning in LVAD is likely to emerge as a key trend in the left ventricle assist devices (LVAD) market during the forecast period.

Europe Left Ventricular Assist Device Market Overview

According to the UK Parliament’s data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Moreover, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. People aged 65 or above are highly prone to cardiovascular diseases and heart failure. With the increasing prevalence of heart failure, the waiting list for heart transplantation is long in the UK. According to a study by the British Heart Foundation, ~300 people were living with LVAD in the UK in 2019, while only ~100 people were living with LVAD in 2012. According to the data provided by the British Geriatrics Society, in 2020, ~1 million people in the UK were living with heart failure, and ~5% of the people admitted to hospitals for emergencies were suffering from heart failure. In 2020, ~2% of the total National Health Service (NHS) expenditure is spent on treatment of heart failure. A surge in the prevalence of heart failure is propelling the growth of the LVAD market in the UK.

Europe Left Ventricular Assist Device Market Revenue and Forecast to 2028 (US$ Million)

Europe Left Ventricular Assist Device Market Segmentation

The Europe left ventricular assist device market is segmented into type of flow, design, application, and country.

Based on type of flow, the Europe left ventricular assist device market is bifurcated into pulsatile flow and non-pulsatile flow. In 2022, the non-pulsatile flow segment registered a larger share in the Europe left ventricular assist device market.

Based on design, the Europe left ventricular assist device market is bifurcated into implantable ventricular assist devices and transcutaneous ventricular assist devices. In 2022, the implantable ventricular assist devices segment registered a larger share in the Europe left ventricular assist device market.

Based on application, the Europe left ventricular assist device market is segmented into Bridge to transplantation, destination therapy, bridge to recovery, and bridge to candidacy. In 2022, the destination therapy segment registered the largest share in the Europe left ventricular assist device market.

Based on country, the Europe left ventricular assist device market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe left ventricular assist device market.

Abbott Laboratories, Medtronic Plc, Evaheart Inc., and CorWave SA are some of the leading companies operating in the Europe left ventricular assist device market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe left ventricular assist device market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Europe left ventricular assist device market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the left ventricular assist device market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution